Neoton 500 (Phosphocreatine Sodium)

Phosphocreatine sodium serves as a rapid phosphate donor in the creatine kinase system, converting ADP back to ATP. This rapid regeneration of ATP supplies energy to cardiac cells during periods of limited oxygen or nutrient delivery, helping preserve contractile function.

The dosage of Neoton 500 is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals calculate the appropriate amount and frequency according to established medical guidelines.

Safety data for phosphocreatine sodium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Neoton 500, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neoton 500 provides direct ATP regeneration via phosphocreatine, whereas many other agents act indirectly by improving blood flow or reducing workload. Compared with agents like trimetazidine, phosphocreatine offers a rapid, substrate‑based energy boost, but clinical choice depends on patient profile and therapeutic goals.

Neoton 500 should be stored at ambient temperature, away from direct sunlight and moisture. Keep the vial in its original packaging until use, and avoid exposing it to extreme temperatures or humidity to maintain product stability.

Neoton 500 is administered by intramuscular injection. A qualified healthcare professional selects an appropriate injection site, prepares the sterile solution according to aseptic technique, and injects the prescribed volume into the muscle.

Serious risks include anaphylactic reactions, severe cardiac arrhythmias, profound hypotension, electrolyte disturbances, thrombophlebitis, and renal impairment. Patients should be monitored closely for any signs of these events, especially during the initial administration.

Neoton 500 should be avoided in individuals with known hypersensitivity to phosphocreatine sodium, severe uncontrolled cardiac arrhythmias, significant renal dysfunction, or in patients where the risk of allergic reaction outweighs potential benefit. Clinicians must assess each patient’s medical history before prescribing.